{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Partial response rate (PRR) was assessed as\n\n* \\> 50% reduction in serum M-protein plus urine M-protein reduction by 90% or \\< 200 mg/24 hr\n* If serum M-protein is not measurable, then \\> 50% reduction in the involved serum free light chain\n* If involved serum free light chain is not measurable, then \\> 50% reduction in the bone marrow plasma cell percentage + \\> 50% reduction in the size of any soft tissue plasmacytoma.","groups":[{"description":"Study treatment is a high-dose sequential chemotherapy approach to hematopoietic stem cell (HSC) transplant that uses an autologous peripheral blood stem cell (auto-PBSC) transplant followed by allogeneic peripheral blood stem cell (allo-PBSC) transplant to evaluate improved graft vs host disease (GvHD) control. Participant auto-PBSC are mobilized with cyclophosphamide (also to provide cytoreduction) and filgrastim, followed by melphalan as an auto-PBSC conditioning agent, then auto-PBSC infusion. For the allo-PBSC transplant, donors are mobilized with filgrastim, and participants receive a regimen of total lymphoid irradiation and anti-thymocyte globulin (TLI/ATG), followed by infusion of donor allo-PBSC. Solumedrol, diphenhydramine, acetaminophen, and hydrocortisone are administered as premedications, and rabbit anti-thymocyte globulin (ATG) plus mycophenolate mofetil (MMF) are administered for post-allo-PBSC immunosuppression.","id":"OG000","title":"Autologous-Allogeneic Peripheral Blood Stem Cell Transplant"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Includes all study participants","reportingStatus":"POSTED","timeFrame":"1 year","title":"Partial Response Rate (PRR)","type":"SECONDARY","unitOfMeasure":"Participants"}